The immune response in multiple sclerosis
S Rodríguez Murúa, MF Farez… - Annual Review of …, 2022 - annualreviews.org
Multiple sclerosis (MS) is a chronic autoimmune, inflammatory, and neurodegenerative
disease that affects the central nervous system (CNS). MS is characterized by immune …
disease that affects the central nervous system (CNS). MS is characterized by immune …
Treatment of multiple sclerosis: a review
Multiple sclerosis (MS) is an autoimmune demyelinating and neurodegenerative disease of
the central nervous system, and the leading cause of nontraumatic neurological disability in …
the central nervous system, and the leading cause of nontraumatic neurological disability in …
Etrasimod as induction and maintenance therapy for ulcerative colitis (ELEVATE): two randomised, double-blind, placebo-controlled, phase 3 studies
WJ Sandborn, S Vermeire, L Peyrin-Biroulet… - The Lancet, 2023 - thelancet.com
Background Etrasimod, a once-daily, oral, sphingosine 1-phosphate (S1P) receptor
modulator that selectively activates S1P receptor subtypes 1, 4, and 5, with no detectable …
modulator that selectively activates S1P receptor subtypes 1, 4, and 5, with no detectable …
Neutrophil membrane‐camouflaged polyprodrug nanomedicine for inflammation suppression in ischemic stroke therapy
Y Zhao, Q Li, J Niu, E Guo, C Zhao, J Zhang… - Advanced …, 2024 - Wiley Online Library
Neuroinflammation has emerged as a major concern in ischemic stroke therapy because it
exacebates neurological dysfunction and suppresses neurological recovery after …
exacebates neurological dysfunction and suppresses neurological recovery after …
Ponesimod compared with teriflunomide in patients with relapsing multiple sclerosis in the active-comparator phase 3 OPTIMUM study: a randomized clinical trial
Importance To our knowledge, the Oral Ponesimod Versus Teriflunomide In Relapsing
Multiple Sclerosis (OPTIMUM) trial is the first phase 3 study comparing 2 oral disease …
Multiple Sclerosis (OPTIMUM) trial is the first phase 3 study comparing 2 oral disease …
Therapeutic advances in multiple sclerosis
Multiple sclerosis (MS) is an autoimmune disease affecting the central nervous system that
causes significant disability and healthcare burden. The treatment of MS has evolved over …
causes significant disability and healthcare burden. The treatment of MS has evolved over …
ECTRIMS/EAN guideline on the pharmacological treatment of people with multiple sclerosis
Background: Multiple sclerosis (MS) is a complex disease with new drugs becoming
available in the past years. There is a need for a reference tool compiling current data to aid …
available in the past years. There is a need for a reference tool compiling current data to aid …
Thinking outside the box: non-canonical targets in multiple sclerosis
Multiple sclerosis (MS) is an immune-mediated disease of the central nervous system that
causes demyelination, axonal degeneration and astrogliosis, resulting in progressive …
causes demyelination, axonal degeneration and astrogliosis, resulting in progressive …
Roles and regulation of microglia activity in multiple sclerosis: insights from animal models
As resident macrophages of the CNS, microglia are critical immune effectors of inflammatory
lesions and associated neural dysfunctions. In multiple sclerosis (MS) and its animal …
lesions and associated neural dysfunctions. In multiple sclerosis (MS) and its animal …
Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (RADIANCE): a multicentre, randomised, 24-month, phase 3 trial
Background Ozanimod is a sphingosine 1-phosphate receptor modulator, which selectively
binds to sphingosine 1-phosphate receptor subtypes 1 and 5 with high affinity. In the …
binds to sphingosine 1-phosphate receptor subtypes 1 and 5 with high affinity. In the …